For example, Fibroblast Growth Factor Receptor 3 (FGFR3) mutations have been confirmed as potent oncogenic drivers in several cancers, and FGFR3 inhibitors may be a novel therapeutic strategy for patients with FGFR3-altered cancer [57]. The gene discussed is FGFR3; the disease is cancer.